12 August 2026 applies to everyone. No industry gets a blanket exemption - not even pharmaceuticals. Any company that cannot present a valid PPWR Declaration of Conformity for its packaging by that date risks being excluded from the market. And this in a sector that is already governed by the German Medicines Act (AMG), the EU Falsified Medicines Directive, GMP requirements, and CSRD reporting.
The good news: pharmaceutical and OTC companies that take a structured approach can build PPWR compliance on top of existing processes and data - if they start now.
This guide explains what the Packaging and Packaging Waste Regulation 2026 (PPWR) concretely means for pharma and OTC packaging, where it intersects with existing regulations, and how you can close your compliance gaps by August 2026.
Why Pharma & OTC face particular challenges
No other segment combines so many regulatory requirements in a single packaging unit as pharma and OTC.
Since 2019, pharmaceutical serialization has been mandatory in the EU for all prescription medicines - every pack must carry a unique 2D data matrix code with serial number, GTIN, batch number, and expiry date. Tamper-evidence features are required by law. Materials must comply with GMP and be migration-neutral. Leaflet requirements prescribe legibility and completeness.
Now PPWR comes on top. From 12 August 2026, every type of packaging placed on the EU market must have a valid PPWR Declaration of Conformity (DoC) - with no transition period.
This means packaging managers, quality managers, and regulatory affairs teams must operate in two regulatory worlds at once. Anyone who approaches this without structure creates double work - and still risks audit gaps.
The regulatory reality: where PPWR meets pharmaceutical law
PPWR is not an isolated environmental regulation. It lands on top of an already dense web of pharmaceutical rules - creating both overlaps and real conflicts.
